Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2751 to 2800 of 4089 results for patient

  1. Macular translocation with 360° retinotomy for wet age-related macular degeneration (HTG216)

    Evidence-based recommendations on macular translocation with 360° retinotomy for wet age-related macular degeneration. This involves cutting and moving the macula on to a nearby healthier area of the choroid layer.

  2. Cyanoacrylate glue for hernia mesh fixation (MIB301)

    NICE has developed a medtech innovation briefing (MIB) on cyanoacrylate glue for hernia mesh fixation .

  3. Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15)

    This guideline covers the risk of early death from heart disease and other smoking-related illnesses. It aims to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.

  4. Smoking: reducing and preventing tobacco use (QS82)

    This quality standard covers reducing and preventing tobacco use in adults, young people and children. It includes interventions to discourage people from taking up smoking, tobacco control strategies and smokefree policies. It is particularly relevant to local authorities, schools and colleges, employers and NHS service providers. It describes high-quality care in priority areas for improvement.

  5. Total wrist replacement (HTG173)

    Evidence-based recommendations on total wrist replacement. This involves creating an artificial wrist joint consisting of metal implants attached to the end of the arm and to the hand, separated by a spacer to allow movement.

  6. Good practice guidance – Integrated process statement (PMG12)

    This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance

  7. Collagen injection for vocal cord augmentation (HTG79)

    Evidence-based recommendations on collagen injection for vocal cord augmentation. This involves injecting collagen into the affected vocal cord(s).

  8. The experiences of people with learning disabilities and mental health problems in services:- What experience do people with learning disabilities have of services designed to prevent and treat mental health problems and how does this relate to clinical outcomes?

    disabilities would help to improve service design, staffing decisions and patient outcomes. This is also an area of national priority,...

  9. Staging investigations for CPG 3 prostate cancer: What is the diagnostic accuracy of staging investigations for CPG 3 prostate cancer?

    However, MDTs will need to be aware of the new 5‑tier model when assessing patient risk. Under the 5‑tier CPG risk stratification model...

  10. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

  11. Percutaneous radiofrequency ablation for atrial fibrillation (HTG110)

    Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.

  12. Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (HTG99)

    Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions). This involves applying (or sometimes injecting) a photosensitising agent and using light to activate it, destroying the tumour cells.

  13. Caesarean birth (NG192)

    This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.

  14. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.

  15. Laparoscopic insertion of peritoneal dialysis catheter (HTG133)

    Evidence-based recommendations on laparoscopic insertion of peritoneal dialysis catheter. This involves inserting a tube through small cuts (keyhole surgery) in the abdomen to remove waste product from the blood.

  16. Automated percutaneous mechanical lumbar discectomy (HTG88)

    Evidence-based recommendations on automated percutaneous mechanical lumbar discectomy. This involves using an automated device to cut and remove the part of the disc that’s pressing on the nerve.

  17. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  19 November 2026

  18. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

  19. Digital self-help for eating disorders: early value assessment (HTG768)

    Early value assessment (EVA) guidance on digital self-help for eating disorders.

  20. Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

    NICE is unable to recommend the use in the NHS of carmustine implants as an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated because no evidence submission was received from the manufacturer or sponsor of the technology. We will review this decision if the company decides to make a submission

    Sections for TA149

  21. Tofacitinib for treating juvenile idiopathic arthritis (TA735)

    Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.

  22. Acumen IQ sensor for predicting hypotension risk (MIB266)

    NICE has developed a medtech innovation briefing (MIB) on Acumen IQ sensor for predicting hypotension risk .

  23. Kidney conditions: AKI register (IND174)

    This indicator covers establishing and maintaining a register of all patients who have had an episode of AKI. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM152

  24. Weight management: referral to weight management programmes for obesity (co-existing hypertension or diabetes) (IND221)

    This indicator covers the percentage of patients with hypertension or diabetes and a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months who have been referred to a weight management programme within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM203

  25. Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

    NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus

  26. Patisiran for treating hereditary transthyretin amyloidosis (HST10)

    Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.

  27. Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)

    Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.

  28. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

  29. Atopic eczema in under 12s: diagnosis and management (CG57)

    This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.

  30. Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

    NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.

    Sections for TA148

  31. Cardiovascular disease prevention: blood pressure measurement every 5 years (IND112)

    This indicator covers the percentage of patients aged 40 years and over with a blood pressure measurement recorded in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM61

  32. Diabetes: NDH diabetes prevention programme (IND171)

    This indicator covers the percentage of patients newly diagnosed with non-diabetic hyperglycaemia in the preceding 12 months who have been referred to a Healthier You: NHS Diabetes Prevention Programme for intensive lifestyle advice. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM149

  33. For women who are having medical abortion between 10 +1   and 12 +0  weeks, what is the efficacy and acceptability of expulsion at home compared with expulsion in a clinical setting?

    home expulsion was performed or between 9+1 and 10+0 weeks. Evidence on patient satisfaction showed it was the same in both groups. The...

  34. Diabetes: advice for erectile dysfunction (IND106)

    This indicator covers the percentage of male patients with diabetes who have a record of erectile dysfunction with a record of advice and assessment of contributory factors and treatment options in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM52

  35. RespiraSense for continuously monitoring respiratory rate (MIB299)

    NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .

  36. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

  37. Drug misuse prevention: targeted interventions (NG64)

    This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.

  38. Antenatal care (NG201)

    This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.

  39. OpenAthens eligibility

    Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account using our online form.

  40. COPD: oxygen saturation recording (IND212)

    This indicator covers the percentage of patients with very severe chronic obstructive pulmonary disease (COPD) with a record of oxygen saturation value within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM194

  41. Scleral expansion surgery for presbyopia (HTG43)

    Evidence-based recommendations on scleral expansion surgery for presbyopia. This involves making small incisions in the eye and inserting bands to stretch part of the sclera.

  42. Stable angina: management (CG126)

    This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.

  43. Stimulated graciloplasty for faecal incontinence (HTG103)

    Evidence-based recommendations on stimulated graciloplasty for faecal incontinence. This involves making a new anal sphincter from muscle taken from the thigh and using electrical currents to gradually make it behave like a natural sphincter muscle.

  44. Optical coherence tomography to guide percutaneous coronary intervention (HTG332)

    Evidence-based recommendations on optical coherence tomography to guide percutaneous coronary intervention. This involves using near-infrared light to produce high-resolution images of blood vessel walls.

  45. clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia (MIB278)

    NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .

  46. Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids (MIB255)

    NICE has developed a medtech innovation briefing (MIB) on the Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids .

  47. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTE10083 Expected publication date: TBC